Samsung Biosimilar Lantus Filings Planned As Pipeline Progresses
This article was originally published in PharmAsia News
Samsung's biosimilar projects seem to be progressing smoothly, with its affiliate Samsung Bioepis in the final stage of a Phase III global clinical study for SB9, its biosimilar version of Sanofi's blockbuster Lantus (insulin glargine), for which an approval filing is planned in the U.S. in the latter half of this year and in Europe early next year.
You may also be interested in...
Samsung Bioepis' biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?